Business
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update
Xenon’s Proprietary Programs Continue to Advance with Multiple Mid to Late Stage Clinical Trials Anticipated to be Underway in 2020 Xenon Eligible for
About this update from Xenon Pharmaceuticals Inc.
[{"type":"text","content":"Xenon’s Proprietary Programs Continue to Advance with Multiple Mid to Late Stage Clinical Trials Anticipated to be Underway in 2020\n Xenon Eligible for Milestone Payments Based on the Advancement of Partnered Programs Experienced Biotech Executive, Dr. Clarissa Desjardins, Joins Xenon’s Board of Directors BURNABY, British Columbia, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today provided a corporate update and outlined its key milestone opportunities for 2020. Dr. Simon Pimstone, Xenon’s Chief Executive Officer, said, “Xenon is entering 2020 in a very strong position with an exciting portfolio of proprietary neurology-focused candidates in clinical development, a healthy balance sheet, and valued collaborators advancing partnered programs. We expect to have multiple mid to late stage clinical trials underway in 2020 putting us in a position to generate important clinical data in 2020.” Dr. Pimstone continued, “We anticipate a number of important milestone events in 2020, including the initiation of a Phase 3 clinical trial with XEN496 in patients with KCNQ2-DEE, a severe and rare form of pediatric epilepsy. In addition to the ongoing XEN1101 Phase 2b clinical trial in adult focal epilepsy, where we anticipate top-line data later this year, we are also seeking to expand the clinical development of XEN1101 in 2020 as we evaluate additional potential clinical indications for this novel Kv7 potassium channel modulator. Additionally, we look forward to the results from a physician-led Phase 2 study examining XEN007 in treatment-resistant childhood absence epilepsy.” Dr. Pimstone added, “We are also fortunate to work with great collaborators who continue to advance our partnered programs. Neurocrine has guided that it expects to file an IND in mid-2020 in order to start a Phase 2 clinical trial for XEN901 (now known as NBI-921352) in SCN8A-DEE pediatric patients. Flexion continues to develop its pre-clinical FX301 program focused on peripheral nerve block for control of post-operative pain, and anticipates initiating FX301 clinical trials in 2021.” Anticipated Milestones Proprietary Programs XEN1101 is a differentiated Kv7 potassium channel modulator being developed for the treatment of epilepsy and potentially other neurological disorders. A Phase 2b doubl...